İş Private Equity, a Turkish firm, has invested $39 million in a Harvard University lab led by Professor Gökhan Hotamışlıgil, focusing on metabolic therapies. This investment also funds a new biotech, Enlila, to develop resulting drug candidates. The deal, considered a potential model for future academic research funding amid budget cuts, provides crucial capital for the lab's work on metabolic conditions.

Prepared by Olivia Bennett and reviewed by editorial team.